

EMADOC-1700519818-1784306

## European Medicines Agency decision EMA/PE/0000182525

of 6 December 2024

on the granting of a product specific waiver for modified messenger ribonucleic acid encoding individual patient-specific tumour neoantigens (V940/mRNA-4157) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

**Only the English text is authentic.**



# European Medicines Agency decision

EMA/PE/0000182525

of 6 December 2024

on the granting of a product specific waiver for modified messenger ribonucleic acid encoding individual patient-specific tumour neoantigens (V940/mRNA-4157) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004<sup>1</sup>,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency<sup>2</sup>,

Having regard to the application submitted by Merck Sharp & Dohme B.V. on 3 July 2024 under Article 13 of Regulation (EC) No 1901/2006,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 18 October 2024 in accordance with Article 13 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee has given an opinion on the granting of a product specific waiver.
- (2) It is therefore appropriate to adopt a decision granting a waiver.

---

<sup>1</sup> OJ L 378, 27.12.2006, p.1, as amended.

<sup>2</sup> OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

**Article 1**

A waiver for modified messenger ribonucleic acid encoding individual patient-specific tumour neoantigens (V940/mRNA-4157), the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

**Article 2**

This decision is addressed to Merck Sharp & Dohme B.V., Waarderweg 39, 2031 BN - Haarlem, Netherlands.



EMADOC-1700519818-1636673

Amsterdam, 18 October 2024

## Opinion of the Paediatric Committee on the granting of a product-specific waiver

EMA/PE/0000182525

### Scope of the application

#### Active substance(s):

Modified messenger ribonucleic acid encoding individual patient-specific tumour neoantigens (V940/mRNA-4157)

#### Invented name and authorisation status:

See Annex II

#### Condition(s):

Treatment of melanoma

#### Pharmaceutical form(s):

Dispersion for injection

#### Route(s) of administration:

Intramuscular use

#### Name/corporate name of the PIP applicant:

Merck Sharp & Dohme B.V.

### Basis for opinion

Pursuant to Article 13 of Regulation (EC) No 1901/2006 as amended, Merck Sharp & Dohme B.V. submitted to the European Medicines Agency on 3 July 2024 an application for a product-specific waiver on the grounds set out in Article 11 of said Regulation for the above mentioned medicinal product.

The procedure started on 19 August 2024.



## **Opinion**

1. The Paediatric Committee, having assessed the waiver application in accordance with Article 13 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
  - to grant a product-specific waiver for all subsets of the paediatric population and all the above mentioned condition(s) in accordance with Article 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified subset(s) of the paediatric population, and Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The grounds for the granting of the waiver are set out in Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

## **Annex I**

### **Grounds for the granting of the waiver**

## **1. Waiver**

### ***1.1. Condition:***

Treatment of melanoma

The waiver applies to:

- the paediatric population from birth to less than 12 years of age;
- dispersion for injection, intramuscular use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

and

- adolescents from 12 years to less than 18 years of age;
- dispersion for injection, intramuscular use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible.

## **Annex II**

### **Information about the authorised medicinal product**

***Information provided by the applicant:***

**The product is not authorised anywhere in the European Community.**